358 related articles for article (PubMed ID: 28583909)
1. Olaparib Keeps Hereditary Breast Tumors in Check.
Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909
[TBL] [Abstract][Full Text] [Related]
2. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
3. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Armstrong AC; Clay V
Future Oncol; 2019 Jul; 15(20):2327-2335. PubMed ID: 31304797
[TBL] [Abstract][Full Text] [Related]
4. Olaparib for the treatment of breast cancer.
Griguolo G; Dieci MV; Guarneri V; Conte P
Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
6. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
7. Olaparib for the treatment of breast cancer.
Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
9. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Matulonis UA; Wulf GM; Barry WT; Birrer M; Westin SN; Farooq S; Bell-McGuinn KM; Obermayer E; Whalen C; Spagnoletti T; Luo W; Liu H; Hok RC; Aghajanian C; Solit DB; Mills GB; Taylor BS; Won H; Berger MF; Palakurthi S; Liu J; Cantley LC; Winer E
Ann Oncol; 2017 Mar; 28(3):512-518. PubMed ID: 27993796
[TBL] [Abstract][Full Text] [Related]
11. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
12. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
13. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Le D; Gelmon KA
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
[TBL] [Abstract][Full Text] [Related]
14. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
[TBL] [Abstract][Full Text] [Related]
15. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
16. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
17. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
19. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Robson M; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Li W; Tung N; Armstrong A; Wu W; Goessl C; Runswick S; Conte P
N Engl J Med; 2017 Aug; 377(6):523-533. PubMed ID: 28578601
[TBL] [Abstract][Full Text] [Related]
20. The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Domchek SM
Clin Adv Hematol Oncol; 2018 May; 16(5):330-332. PubMed ID: 29851928
[No Abstract] [Full Text] [Related]
[Next] [New Search]
